Novartis’ remibrutinib delivered positive top-line Phase 3 results in relapsing multiple sclerosis, marking the second oral BTK inhibitor to post favorable Phase 3 readouts. The company’s data positions remibrutinib behind Roche’s fenebrutinib in the race to be the first BTK inhibitor approved for relapsing MS. The competitive field has previously seen efficacy or safety difficulties among other BTK candidates, making the latest positive signal a key data point for regulators deciding whether this class can be safely translated into broader chronic MS use.